Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Pulmonary Sarcoidosis
NCT02888080Phase 2Completed
- Sponsor
- Novartis
- Start
- Dec 2016
- Primary completion
- Mar 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of canakinumab in pulmonary sarcoidosis, sponsored by Novartis. Started Dec 2016; status: completed.
02
Drugs
canakinumab
03
Conditions
pulmonary sarcoidosis
Beyond the preview
Go deeper on NCT02888080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02888080.